|
|
| | EBE-A 22 Basic information |
| Product Name: | EBE-A 22 | | Synonyms: | EBE-A 22;N-(3-Bromophenyl)-6,7-dimethoxy-N-methyl-4-quinazolinamine;N-(3-bromophenyl)-6,7-dimethoxy-N-methylquinazolin-4-amine;4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-N-methyl-;EBE-A22, >98%;PD153035 Analog 63;inhibit,Inhibitor,EBE-A-22,EBE A22,EBE-A22,EBEA22 | | CAS: | 229476-53-3 | | MF: | C17H16BrN3O2 | | MW: | 374.23 | | EINECS: | | | Product Categories: | | | Mol File: | 229476-53-3.mol |  |
| | EBE-A 22 Chemical Properties |
| Boiling point | 507.3±50.0 °C(Predicted) | | density | 1.446±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 50 mg/mL (133.61 mM); Water: < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 5.65±0.30(Predicted) | | color | White to off-white |
| | EBE-A 22 Usage And Synthesis |
| Uses | EBE-A 22 is an epidermal growth factor receptor inhibitor EGFR, an important target for the treatment of cancer. Selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| | EBE-A 22 Preparation Products And Raw materials |
|